EXEL240920C18000
- 8.64
- -0.98-10.19%
Exelixis Newsroom
UBS Initiates Exelixis at Neutral
UBS Initiates Exelixis(EXEL.US) With Hold Rating, Announces Target Price $30
UBS analyst Ashwani Verma initiates coverage on $Exelixis(EXEL.US)$ with a hold rating, and sets the target price at $30.According to TipRanks data, the analyst has a success rate of 46.2% and a
HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $29 Price Target
Exelixis Analyst Ratings
Exelixis Unveils Additional Data on Cabometyx for Neuroendocrine Tumors
Citi Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $31
Citi analyst David Lebovitz maintains $Exelixis(EXEL.US)$ with a buy rating, and maintains the target price at $31.According to TipRanks data, the analyst has a success rate of 50.2% and a total
Exelixis (EXEL) Gets a Hold From Stifel Nicolaus
Wells Fargo Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $32
Wells Fargo analyst Derek Archila maintains $Exelixis(EXEL.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 48.3% and a
H.C. Wainwright Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright analyst Robert Burns maintains $Exelixis(EXEL.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 30.9% and a
Exelixis (EXEL) Stock Buy Rating Affirmed on Promising Subgroup Data and Market Opportunity in MCRPC Treatment
Ipsen Nixes Plans to Commercialize Prostate Cancer Treatment
Exelixis Announces Final Results From Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
Express News | Exelixis Inc - Phase 3 Contact-02 Trials Show Numerical but Not Significant Os Improvement
Express News | Exelixis Presents Final Overall Survival Results From Phase 3 Contact-02 Pivotal Study Evaluating Cabozantinib in Combination With an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at Esmo 2024
Exelixis, Inc. (EXEL): Among Hedge Funds' Top Biotech Stock Picks
Daily short sale tracking: Bank Bradesco SA(prefer share ADS)'s short volume increased by 4 million, with a short sale ratio of 17%
Bank Bradesco SA(prefer share ADS)(BBD.US) ranked top of the list had the largest change in short volume (4.11 million shares), and the short volume ratio of Exelixis(EXEL.US) reached 46.32%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Does Exelixis (NASDAQ:EXEL) Deserve A Spot On Your Watchlist?
Unusual Options Activity: OVV, KKR and Others Attract Market Bets, OVV V/OI Ratio Reaches 190.3
EST Sep 10th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Optimistic Outlook for Exelixis With Growth Opportunities in Drug Development Pipeline
BofA Securities Maintains Exelixis(EXEL.US) With Buy Rating
BofA Securities analyst Jason Gerberry maintains $Exelixis(EXEL.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.7% and a total average return of 0.2% over the